Author: Kevin Grogan

Daiichi Sankyo has delved into the European antibody market and acquired privately-owned German biotechnology group U3 Pharma in a bid to boost its oncology pipeline.

As part of their probe into direct-to-consumer advertising of prescription drugs, the two US Congressmen heading the investigation have written to the chief executives of four major drugmakers requesting improved accuracy and stronger guidelines in adverts.

At long last, GlaxoSmithKline and partner Adolor Corp have received the thumbs-up from US regulators for their new bowel drug Entereg.

Switzerland-based Nycomed has posted a dip in first-quarter sales due to generic competition to the gastrointestinal drug pantoprazole in the USA but chief executive Hakan Bjorklund told PharmaTimes World News that the firm is doing well elsewhere and intends to forge further ahead in the emerging markets.

Skyepharma has moved to ease concerns among investors who are worried about the firm’s ability to refinance the terms of convertible bonds that could result in liabilities of almost £90 million over the next two years.